Efficacy of Extracorporeal Shockwave Myocardial Revascularization

NCT01711099 | Unknown

• 1 other identifier: ANGEL_v01
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 2

Brief Summary

Clinical research to justify effectiveness of the Extracorporeal Shockwave Myocardial Revascularization (ESMR) Therapy for treatment of patients with reversible myocardial ischemia secondary to Coronary Artery Disease (CAD) and therapy resistant stable angina pectoris.

Conditions

Refractory Angina Pectoris

Outcome Measures

Primary Outcomes (1)

• Improvement in myocardial ischaemia profile during dobutamine induced stress echocardiography

  baseline and 6 months

Secondary Outcomes (5)

• Improvement in the angina pectoris CCS Stage

  baseline and 3, 6 months

• Improvement in angina status using Seattle Angina Questionnaire

  baseline and 3, 6 months

• The change in walking time using the modified Bruce exercise test

  baseline and 3, 6 months

• The change in basal transthoracal echocardiographic parameters

  baseline and 3, 6 months

• The decrease in nitrate use during the unchanged everyday activity reported by the patients in the "Nitrate Usage Log"

  baseline and 3, 6 months

Study Arms (1)

ESMR treated

EXPERIMENTAL

Device: device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy

Interventions

device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy DEVICE

Also known as: Cardiospec system

ESMR treated

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient with a signed Informed Consent Form.
• Patient's current and past medical condition and status be assessed using previous medical history, complete physical examination and the physicians (principle investigator's) medical opinion.
• Patient is diagnosed with chronic angina pectoris for at least 6 weeks. Diagnosis is based on medical history, complete physical examination, and core labs.
• Patients who no longer receive benefit from additional revascularization procedures (i.e. CABG or Angioplasty). Certification will be made by Heart Team.
• Patient demonstrates Exercise Tolerance Time (ETT) duration \< 10 minutes on Modified Bruce protocol.
• Patient had at least one documented myocardial segment with reversible ischemia.
• Patient is under optimum medical therapy for angina for at least 6 weeks. The optimal treatment plan is tailored to a person's age, the presence of other medical conditions, lifestyle, medication side effects, etc. Medical therapies for stable angina include ACE-inhibitors, Nitrates, Beta Blockers and Calcium Channel Blockers, trimetazidine, ivabradin. Combination of any of 3 above mentioned drugs will be considered as optimum medical therapy.
• Patient has an echocardiographic acoustic window to the target area in the myocardium utilizing one of the following views: apical 2 chamber view (2CH), apical 4 chamber view (4CH), modified parasternal long axis view (LAX) and parasternal short axis view (SAX).

You may not qualify if:

• Patient who will substantially benefit from additional revascularization procedures such as additional CABG or angioplasty therapies. This determination will be made and certified by the Heart Team.
• Patient has active endocarditis, myocarditis or pericarditis.
• Patient with moderately severe or severe valvular disease.
• Patient with known intraventricular thrombus.
• Patients who have active or non-active implantables, such as pacemakers, defibrillators, abandoned leads, or electrodes.
• Patient for who shock waves applied over any implanted device that releases substances or medications to the periphery (such as insulin pumps).
• Patient is pregnant.
• Patient with severe chronic lung disease (emphysema, pulmonary fibrosis) with difficult access to ultrasonic acoustic window.
• Patients for who shock waves applied over the area of healing fracture.
• Patients for who shock waves applied over the area of bone growth.
• Patients for who shock waves applied to the area of malignancy.
• Prior invasive malignancy, except non-melanomatous skin cancer or other malignancies with a documented disease-free survival for a minimum of 5 years.
• By the physician decision there is underlying concomitant disease or circumstance what may negatively influence the management of the patient.

Sponsors & Collaborators

• Salus Ltd.: lead

Study Sites (2)

Kelen Hospital

Budapest, Hungary

RECRUITING

Semmelweis University Heart Center

Budapest, Hungary

RECRUITING

MeSH Terms

Conditions

Angina Pectoris

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Chest Pain; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Béla Merkely, Prof

  Semmelweis University Heart Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Béla Merkely, Prof.

CONTACT

+36 1 4586840; titkarsag@kardio.sote.hu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 16, 2012
• First Posted: October 22, 2012
• Study Start: October 1, 2012
• Primary Completion: September 1, 2013
• Last Updated: October 25, 2012

Record last verified: 2012-10

Locations

HU (2)